These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 9377731)

  • 21. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
    Palmieri V; Devereux RB
    Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study.
    Iino Y; Hayashi M; Kawamura T; Shiigai T; Tomino Y; Yamada K; Kitajima T; Ideura T; Koyama A; Sugisaki T; Suzuki H; Umemura S; Kawaguchi Y; Uchida S; Kuwahara M; Yamazaki T;
    Clin Exp Nephrol; 2003 Sep; 7(3):221-30. PubMed ID: 14586719
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Arterial hypertension and proteinuria in pediatric chronic kidney disease.
    Simonetti GD; Bucher BS; Tschumi S; Lava SA; Bianchetti MG
    Minerva Pediatr; 2012 Apr; 64(2):171-82. PubMed ID: 22495191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Calcium channel blockers versus angiotensin-converting enzyme inhibitors: renal effects.
    Linas S
    Am J Kidney Dis; 1990 Oct; 16(4 Suppl 1):15-9. PubMed ID: 2220796
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RAS inhibition in hypertension.
    Ibrahim MM
    J Hum Hypertens; 2006 Feb; 20(2):101-8. PubMed ID: 16397519
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiotensin receptor blockers in chronic renal disease: the promise of a bright clinical future.
    Mackenzie HS; Ziai F; Omer SA; Nadim MK; Taal MW
    J Am Soc Nephrol; 1999 Apr; 10 Suppl 12():S283-6. PubMed ID: 10201884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic effects of angiotensin II inhibition or blockade on the progression of chronic renal disease.
    Cantarovich F; Rangoonwala B
    Int J Clin Pract; 2003 Nov; 57(9):801-22. PubMed ID: 14686572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of ACE inhibitors and calcium antagonists on progression of chronic renal disease.
    Epstein M
    Blood Press Suppl; 1995; 2():108-12. PubMed ID: 7582066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison between the antiproteinuric effects of the calcium channel blockers benidipine and cilnidipine in combination with angiotensin receptor blockers in hypertensive patients with chronic kidney disease.
    Abe M; Okada K; Maruyama N; Matsumoto S; Maruyama T; Fujita T; Matsumoto K; Soma M
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1027-37. PubMed ID: 20649501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Calcium antagonists-ACE inhibitors combination therapy: objectives and methodology of clinical development.
    Menard J; Bellet M
    J Cardiovasc Pharmacol; 1993; 21 Suppl 2():S49-54. PubMed ID: 7692151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiotensin converting enzyme inhibitors, calcium channel blockers, and their combination in the treatment of glomerular disease.
    Ritz E; Orth SR; Strzelczyk P
    J Hypertens Suppl; 1997 Mar; 15(2):S21-6. PubMed ID: 9218194
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of calcium antagonists in patients with chronic renal failure.
    Rahn KH
    Pediatr Nephrol; 2005 Sep; 20(9):1208-13. PubMed ID: 15971071
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Do angiotensin converting enzyme and calcium channel blocker intervene in the progression of renal disease besides by lowering systemic hypertension?].
    Nagase M
    Nihon Rinsho; 1997 Aug; 55(8):2116-22. PubMed ID: 9284433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the effects of ACE inhibitors and calcium channel blockers on the progression of renal failure.
    Zucchelli P; Zuccalà A; Gaggi R
    Nephrol Dial Transplant; 1995 Oct; 10 Suppl 9():46-51. PubMed ID: 8643208
    [No Abstract]   [Full Text] [Related]  

  • 35. Can we slow the progression of chronic kidney disease?
    Wühl E; Schaefer F
    Curr Opin Pediatr; 2010 Apr; 22(2):170-5. PubMed ID: 20042976
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renal haemodynamic and protective effects of calcium antagonists in hypertension.
    Zanchi A; Brunner HR; Waeber B; Burnier M
    J Hypertens; 1995 Dec; 13(12 Pt 1):1363-75. PubMed ID: 8866898
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The case for combining angiotensin-converting enzyme inhibitors and calcium-channel blockers.
    Taylor AA; Sunthornyothin S
    Curr Hypertens Rep; 1999 Oct; 1(5):446-53. PubMed ID: 10981104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of combination therapy with ACE inhibitors and calcium channel blockers in renal protection.
    Locatelli F; Del Vecchio L; Andrulli S; Colzani S
    Kidney Int Suppl; 2002 Dec; (82):S53-60. PubMed ID: 12410856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Angiotensin II receptor antagonists].
    Chung O; Unger T
    Internist (Berl); 1996 May; 37(5):534-8; discussion 538. PubMed ID: 9011557
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of ACE inhibitors, calcium channel blockers and their combination on renal and extrarenal structures in renal failure.
    Amann K; Törnig J; Nichols C; Zeier M; Mall G; Ritz E
    Nephrol Dial Transplant; 1995 Oct; 10 Suppl 9():33-8. PubMed ID: 8643206
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.